Abstract 200P
Background
Understanding the complex biology of metastatic tumors is critical for advancing cancer biology research and improving therapeutic interventions. To address this challenge, we have developed a novel multi-organ-on-chip (Multi-OOC) platform designed to unravel the intricacies of breast to bone (B2B) metastatic tumor growth. This innovative platform integrates organ-specific tissue models fluidically interconnected to mimic the dynamic interactions between primary tumor and distant organ during metastasis. By replicating the physiological microenvironments of various target organs, our model provides a unique opportunity to investigate the entire metastatic cascade, from tumor cell dissemination, circulating tumor cells (CTCs) survival under flow and colonization. In order to support real-time monitoring of cellular infiltration and response to therapeutic agents in a multi-organ context optically transparent OOC device has been developed, compatible with the optical microscope observation.
Methods
A breast cancer cell laden hydrogel has been developed by using MDA-MB-231 cells with and without endothelial cells (HUVEC), forming the capillary network. A computational fluid dynamic simulation was done to set up the proper capillary velocity and induced shear stresses. In a second chamber, a bone tissue model was developed as metastasis target: different ratio of hydroxyapatite (HA) has been included in a polymeric matrix to introduce a bone like mineral phase. Tumor cell infiltration and CTC survival rate have been monitored using different fluid-dynamic conditions and HA content.
Results
A multicompartmental OOC has been developed and successfully validated. The 3D breast cancer model displayed long term (2 months) survival in vitro in dynamic conditions, and a cells cytoskeleton reorganization was highlighted. The CTCs survival was shown correlated to the shear stresses induced by the fluid flow into the Multi-OOC. Different levels of CTCs infiltration in the mineralized matrix hosted in the metastatic OOC chamber were observed.
Conclusions
This platform holds great promise for accelerating the development of targeted therapies and personalized treatment strategies, ultimately advancing our understanding of metastatic cancer biology.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Aiello, S. Scaglione: Financial Interests, Personal, Member of Board of Directors: React4life. All other authors have declared no conflicts of interest.
Resources from the same session
146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses
Presenter: David Pejoski
Session: Poster Display
147P - Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020
Presenter: Geneviève Gueguen Dorbes
Session: Poster Display
148P - HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo
Presenter: Kristel Kemper
Session: Poster Display
149P - HLA/SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses
Presenter: anahita rafiei
Session: Poster Display
150P - Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer
Presenter: Eunice Dotse
Session: Poster Display
151P - Tumor organoid-derived TIL therapy for colorectal cancer
Presenter: Marc Leushacke
Session: Poster Display
152P - Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are functional in high adenosine environment
Presenter: Nainesh Katagihallimath
Session: Poster Display
153P - Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer
Presenter: James Levin
Session: Poster Display
154P - Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer
Presenter: Yi Xu
Session: Poster Display
155P - A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors
Presenter: Hans Prenen
Session: Poster Display